245 Main Street
Second Floor
Cambridge, MA 02142
United States
617 500 8080
https://immuneering.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 65
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Benjamin J. Zeskind M.B.A., Ph.D. | Co-Founder, President, CEO & Director | 935.09k | N/A | 1983 |
Mr. Robert J. Carpenter M.B.A., M.S. | Co-Founder & Chair Emeritus | 75.36k | N/A | 1946 |
Dr. Brett M. Hall Ph.D. | Chief Scientific Officer | 905.41k | N/A | 1969 |
Mr. Harold E. Brakewood | Chief Business Officer | 579.77k | N/A | 1966 |
Ms. Mallory Morales CPA | Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer | N/A | N/A | 1984 |
Ms. Paula George CPA | Director of Accounting & Operations and Assistant Corporate Controller | N/A | N/A | N/A |
Mr. Michael D. Bookman J.D. | Chief Legal Officer & Secretary | N/A | N/A | 1987 |
Ms. Leah R. Neufeld | Chief People Officer | N/A | N/A | 1973 |
Dr. Peter King Ph.D. | Head of Discovery & VP | N/A | N/A | N/A |
Dr. Praveen Nair Ph.D. | Head of Translational Pharmacology & VP | N/A | N/A | N/A |
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Immuneering Corporation’s ISS governance QualityScore as of 1 June 2024 is 8. The pillar scores are Audit: 6; Board: 6; Shareholder rights: 7; Compensation: 9.